Stocks · News reference

Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72

Oct 9, 2026, 11:25 AMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 9, 2026, 11:25 AM
Checked: Oct 9, 2026, 11:25 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 9, 2026, 6:43 PMBenzinga Newsdesk
Quince Therapeutics shares are trading higher after Raymond James initiated its coverage on the stock with an Outperform rating and announced a price target of $72. Also, the company announced that it has changed its name to IRulya Therapeutics, effective on October 12.
QNCX
Globenewswire IncOct 9, 2026, 12:00 PMNa
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics has rebranded to IRulya Therapeutics and will trade on Nasdaq under ticker 'IRLA' starting October 12, 2026. The company is focused on advancing LAM-001, an inhaled rapamycin formulation for pulmonary diseases including PH-ILD, BOS, and SAPH. New leadership has been appointed including CEO Brigette Roberts, M.D., and the company has a cash balance of $116 million expected to fund operations through end of 2028.
QNCX
BenzingaOct 9, 2026, 12:04 PMBenzinga Newsdesk
Quince Therapeutics Announces Appointment Of Brigette Roberts As CEO, John Militello As CFO, And Keith Fandrick As COO; CEO Dirk Thye And COO Brendan Hannah Resign
QNCX
BenzingaOct 9, 2026, 12:04 PMBenzinga Newsdesk
Quince Therapeutics Announces Name Change To IRulya Therapeutics And Nasdaq Ticker Change From QNCX To IRLA, Effective October 12
QNCX